# TOPAZ-1 (NCT03875235)

> Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03875235
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Biliary Tract Neoplasms
- Interventions: Durvalumab; Placebo
- Enrollment: 810
- Primary outcome: Overall Survival (OS)
- Primary outcome: Overall Survival (OS) Rate at 18 Months
- Primary outcome: Overall Survival (OS) Rate at 24 Months

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 88
- YouTube: 48
- Podcasts: 47

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=topaz-1-nct03875235

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03875235", "email": "<work email>"}; the inbox owner confirms by the emailed link.